Please assess the completion status of the following clinical trial:

Trial Title: 18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Patient with CRPC and experiencing disease progression as defined by PCWG2~* ECOG 0-2~* Must continue gonadal castrative therapy~* Has completed antiandrogen withdrawal ≥ 6 weeks prior to registration~* Metastatic disease documented by imaging~* Patient is planned for treatment with docetaxel or abiraterone~* If treated with bisphosphonates or denosumab, has been on these for ≥ 6 weeks.~* Must provide written informed consent~Exclusion Criteria:~* Prior history of invasive malignant disease unless disease free for at least 5 years, with the exception of non-melanoma skin cancer~* Planned for any concurrent anticancer treatment oher than docetaxel or abiraterone~* Prior radiotherapy or surgery within 4 weeks of start of docetaxel or abiraterone~* Inability to comply with the imaging requirements (eg. inability to lie supine for one hour)~* Allergy to MRI contrast agent or PET tracer to be used as part of the imaging~* Sickle cell disease or other hemoglobinopathies~* Insufficient renal function (eGFR ≤ 30 mL/min)~* Known residual bladder volume \> 150 cc~* Hip prosthesis or intrabdominal vascular grafting~* Contraindication to CT contrast~* Contraindication to MRI as per institutional policy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel (Type: OTHER): Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a \[F-18\]-FCH PET scan with full body MRI scan
- Abiraterone (Type: OTHER): Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a \[F-18\]-FCH PET scan with full body MRI scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).